|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
WO1987000201A1
(en)
|
1985-07-05 |
1987-01-15 |
Whitehead Institute For Biomedical Research |
Epithelial cells expressing foreign genetic material
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
US4863457A
(en)
|
1986-11-24 |
1989-09-05 |
Lee David A |
Drug delivery device
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
EP0633318A1
(en)
|
1987-09-11 |
1995-01-11 |
Whitehead Institute For Biomedical Research |
Transduced fibroblasts and uses therefor
|
|
DE3851153T2
(de)
|
1987-12-11 |
1995-01-05 |
Hughes Howard Med Inst |
Genetische modifizierung von endothelialen zellen.
|
|
EP0400047B1
(en)
|
1988-02-05 |
1997-04-23 |
Whitehead Institute For Biomedical Research |
Modified hepatocytes and uses therefor
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5164188A
(en)
|
1989-11-22 |
1992-11-17 |
Visionex, Inc. |
Biodegradable ocular implants
|
|
JP3418982B2
(ja)
|
1990-10-31 |
2003-06-23 |
ソマティクス セラピー コーポレイション |
内皮細胞の遺伝的変性
|
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
BR9306765A
(pt)
|
1992-07-23 |
1998-12-08 |
Minnesota Mining & Mfg |
Processo para a preparação de uma partícula abrasiva e artigo abrasivo
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
EP0656946B2
(en)
|
1992-08-21 |
2010-03-31 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
IT1265573B1
(it)
|
1993-09-17 |
1996-11-22 |
Zanussi Grandi Impianti Spa |
Forno di cottura di alimenti con porta perfezionata
|
|
US5308341A
(en)
|
1993-09-28 |
1994-05-03 |
Becton, Dickinson And Company |
Method of testing the dose accuracy of a medication delivery device
|
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
|
ATE264096T1
(de)
|
1994-03-07 |
2004-04-15 |
Nektar Therapeutics |
Verfahren und mittel zur verabreichung von insulin über die lunge
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
|
CA2229043C
(en)
|
1995-08-18 |
2016-06-07 |
Morphosys Gesellschaft Fur Proteinoptimierung Mbh |
Protein/(poly)peptide libraries
|
|
US5773019A
(en)
|
1995-09-27 |
1998-06-30 |
The University Of Kentucky Research Foundation |
Implantable controlled release device to deliver drugs directly to an internal portion of the body
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
AU3117697A
(en)
|
1996-05-06 |
1997-11-26 |
Uab Research Foundation, The |
Radiolabeled fusion toxins for cancer therapy
|
|
US6146361A
(en)
|
1996-09-26 |
2000-11-14 |
Becton Dickinson And Company |
Medication delivery pen having a 31 gauge needle
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
GB9626960D0
(en)
|
1996-12-27 |
1997-02-12 |
Glaxo Group Ltd |
Valve for aerosol container
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US6096872A
(en)
|
1997-10-14 |
2000-08-01 |
Ortho Diagnostic Systems, Inc. |
Viral clearance process
|
|
NZ504021A
(en)
|
1997-10-17 |
2003-04-29 |
Systemic Pulmonary Delivery Lt |
Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6302855B1
(en)
|
1998-05-20 |
2001-10-16 |
Novo Nordisk A/S |
Medical apparatus for use by a patient for medical self treatment of diabetes
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
HK1042234A1
(zh)
|
1999-04-13 |
2002-08-09 |
Nektar Therapeutics |
向肺部施加乾粉配方以治疗不育症
|
|
WO2000061178A1
(en)
|
1999-04-13 |
2000-10-19 |
Inhale Therapeutics Systems, Inc. |
Pulmonary administration of dry powder formulations for treating infertility
|
|
US6192891B1
(en)
|
1999-04-26 |
2001-02-27 |
Becton Dickinson And Company |
Integrated system including medication delivery pen, blood monitoring device, and lancer
|
|
GB9910975D0
(en)
|
1999-05-13 |
1999-07-14 |
Univ Strathclyde |
Rapid dehydration of proteins
|
|
US6277099B1
(en)
|
1999-08-06 |
2001-08-21 |
Becton, Dickinson And Company |
Medication delivery pen
|
|
PE20011227A1
(es)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
|
AU2001278716A1
(en)
|
2000-08-10 |
2002-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Method of inhibiting antibody-containing solution from coagulating or becoming turbid
|
|
AU2001271417B2
(en)
|
2000-08-30 |
2006-10-05 |
Johns Hopkins University |
Devices for intraocular drug delivery
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
JP4383168B2
(ja)
|
2001-09-12 |
2009-12-16 |
ベクトン・ディキンソン・アンド・カンパニー |
マイクロ針投与デバイスおよび薬物投与デバイス
|
|
JP4021194B2
(ja)
|
2001-12-28 |
2007-12-12 |
シャープ株式会社 |
薄膜トランジスタ装置の製造方法
|
|
WO2003074679A2
(en)
|
2002-03-01 |
2003-09-12 |
Xencor |
Antibody optimization
|
|
WO2003105757A2
(en)
|
2002-06-12 |
2003-12-24 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
|
EP1545611B1
(en)
|
2002-09-06 |
2016-11-09 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
|
US9415102B2
(en)
*
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US20040102469A1
(en)
|
2002-09-13 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for reducing the mortality rate
|
|
GB0222023D0
(en)
|
2002-09-21 |
2002-10-30 |
Aventis Pharma Ltd |
Inhaler
|
|
CA2499816C
(en)
|
2002-09-27 |
2013-07-30 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
FR2849436B1
(fr)
|
2002-12-27 |
2007-01-05 |
Patrick Frayssinet |
Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
|
|
WO2004073551A2
(en)
|
2003-02-18 |
2004-09-02 |
Massachusetts Eye And Ear Infirmary |
Transscleral drug delivery device and related methods
|
|
DK1610820T4
(da)
|
2003-04-04 |
2013-11-04 |
Genentech Inc |
Høj-koncentration antistof- og proteinformuleringer
|
|
US20050054048A1
(en)
|
2003-07-29 |
2005-03-10 |
Luigi Grasso |
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
GB0416328D0
(en)
|
2004-07-21 |
2004-08-25 |
Univ Cardiff |
Use of dry powder compositions for pulmonary delivery
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2006094234A1
(en)
|
2005-03-03 |
2006-09-08 |
Xencor, Inc. |
Methods for the design of libraries of protein variants
|
|
WO2006105338A2
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
WO2007076062A2
(en)
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
|
US7807378B2
(en)
*
|
2005-12-29 |
2010-10-05 |
Industrial Technology Research Institute (Itri) |
Method of diagnosing myasthenia gravis and kits therefor
|
|
EP1988882B1
(en)
|
2006-03-02 |
2014-12-17 |
Alexion Pharmaceuticals, Inc. |
Prolongation of survival of an allograft by inhibiting complement activity
|
|
DK2359834T5
(en)
|
2006-03-15 |
2017-02-06 |
Alexion Pharma Inc |
Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
|
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
US8037880B2
(en)
|
2006-04-07 |
2011-10-18 |
The University Of Western Ontario |
Dry powder inhaler
|
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
|
WO2008048545A2
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
AU2008266051B2
(en)
|
2007-06-14 |
2014-07-31 |
Biogen Ma Inc. |
Antibody formulations
|
|
CN101848733A
(zh)
|
2007-07-13 |
2010-09-29 |
艾博特生物技术有限公司 |
用于肺部给予TNFα抑制剂的方法和组合物
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
ES2742268T3
(es)
|
2007-12-26 |
2020-02-13 |
Xencor Inc |
Variantes de Fc con unión alterada a FcRn
|
|
PT2708559T
(pt)
|
2008-04-11 |
2018-05-16 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
|
|
WO2010015608A1
(en)
|
2008-08-05 |
2010-02-11 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
|
CA2739429C
(en)
|
2008-10-14 |
2020-12-22 |
Lisa A. Damico |
Immunoglobulin variants and uses thereof
|
|
RS64039B1
(sr)
*
|
2008-11-10 |
2023-04-28 |
Alexion Pharma Inc |
Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
|
|
AU2015227544B2
(en)
|
2008-11-10 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
US20120282654A1
(en)
|
2009-04-29 |
2012-11-08 |
Schering Corporation |
Antibody purification
|
|
NZ597259A
(en)
|
2009-06-23 |
2014-04-30 |
Alexion Pharma Inc |
Bispecific antibodies that bind to complement proteins
|
|
WO2011104381A2
(en)
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
CN105218674A
(zh)
|
2010-03-11 |
2016-01-06 |
瑞纳神经科学公司 |
呈pH依赖性抗原结合的抗体
|
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
|
CA2798120A1
(en)
|
2010-04-30 |
2011-11-03 |
Paul P. Tamburini |
Antibodies having reduced immunogenicity in a human
|
|
KR101800913B1
(ko)
|
2010-04-30 |
2017-12-20 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항-c5a 항체들과 이 항체들을 이용하는 방법
|
|
MX365235B
(es)
|
2010-11-30 |
2019-05-28 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
|
|
TWI803876B
(zh)
|
2011-03-28 |
2023-06-01 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
DK2698431T3
(da)
|
2011-03-30 |
2020-11-30 |
Chugai Pharmaceutical Co Ltd |
Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
|
|
JP2014520148A
(ja)
|
2011-06-20 |
2014-08-21 |
セントルイス ユニバーシティ |
治療のための神経筋接合部への標的化
|
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
ES2746103T3
(es)
|
2012-04-30 |
2020-03-04 |
Medimmune Llc |
Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas
|
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
PL2970974T3
(pl)
|
2013-03-14 |
2018-01-31 |
Alnylam Pharmaceuticals Inc |
Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
NZ631007A
(en)
*
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
WO2016100190A1
(en)
|
2014-12-16 |
2016-06-23 |
Novartis Ag |
Low-water content acrylate-acrylamide copolymers for ophthalmic devices
|
|
HUE056489T2
(hu)
|
2014-12-19 |
2022-02-28 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antitestek és alkalmazási eljárások
|
|
EP3236772A4
(en)
|
2014-12-22 |
2018-10-17 |
Alexion Pharmaceuticals, Inc. |
Methods of purifying recombinant proteins
|
|
US20190135903A1
(en)
|
2015-03-31 |
2019-05-09 |
Alexion Pharmaceuticals, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
|
|
US20180311299A1
(en)
|
2015-05-01 |
2018-11-01 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
US20180142010A1
(en)
|
2015-06-26 |
2018-05-24 |
Alexion Pharmaceuticals, Inc. |
Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
|
JP2018528218A
(ja)
|
2015-09-11 |
2018-09-27 |
アンドリアン、ブルース |
組換えグリコシル化エクリズマブおよびエクリズマブ変異体
|
|
AU2016329034B2
(en)
|
2015-09-22 |
2019-05-23 |
Pfizer Inc. |
Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
|
|
ES2986888T3
(es)
|
2015-10-30 |
2024-11-13 |
Alexion Pharma Inc |
Un método para inhibir las exacerbaciones de la vasculopatía del aloinjerto mediada por células T
|
|
US20190023775A1
(en)
|
2016-01-11 |
2019-01-24 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
|
JP2019517473A
(ja)
|
2016-05-27 |
2019-06-24 |
アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
難治性全身型重症筋無力症の処置のための方法
|
|
MY191668A
(en)
|
2016-06-14 |
2022-07-06 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
WO2018044858A2
(en)
*
|
2016-08-29 |
2018-03-08 |
The Cleveland Clinic Foundation |
C5 immunization for autologous anti-c5 antibody production
|
|
US20190276524A1
(en)
|
2016-10-12 |
2019-09-12 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
EP3554543A4
(en)
|
2016-12-16 |
2020-09-02 |
Samsung Bioepis Co., Ltd. |
STABLE Aqueous ANTI-C5 ANTIBODY COMPOSITION
|
|
CN110167961A
(zh)
|
2017-01-31 |
2019-08-23 |
中外制药株式会社 |
用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
|
|
ES2965486T3
(es)
|
2017-07-27 |
2024-04-15 |
Alexion Pharma Inc |
Formulaciones de anticuerpos anti-C5 de alta concentración
|
|
KR20200070355A
(ko)
|
2017-10-26 |
2020-06-17 |
알렉시온 파마슈티칼스, 인코포레이티드 |
발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
|
|
TW201938184A
(zh)
|
2017-12-04 |
2019-10-01 |
美商Ｒａ製藥公司 |
補體活性之調節劑
|
|
ES2996257T3
(en)
|
2018-05-31 |
2025-02-12 |
Alexion Pharma Inc |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
EP3802603A1
(en)
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
|
|
WO2020006266A1
(en)
|
2018-06-28 |
2020-01-02 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-c5 antibodies
|
|
US12240893B2
(en)
|
2018-10-30 |
2025-03-04 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
|
|
EP3914617B1
(en)
|
2019-01-25 |
2024-03-13 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)
|
|
WO2020168079A1
(en)
|
2019-02-14 |
2020-08-20 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
|
|
WO2021091937A1
(en)
|
2019-11-08 |
2021-05-14 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-c5 antibody formulations
|
|
EP4295905A1
(en)
|
2020-07-09 |
2023-12-27 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
CA3196434A1
(en)
|
2020-10-23 |
2022-04-28 |
Krista K. JOHNSON |
Methods of treating patients having complement disorders using anti-c5 antibodies
|
|
WO2023287991A1
(en)
|
2021-07-14 |
2023-01-19 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
|